Ranitidine is a commonly used drug, classified as a histamine H2-receptor antagonist, and belongs to the same drug class as cimetidine and famotidine. This drug helps to prevent and treat gastric-acid associated conditions, including ulcers, because of its ability to decrease gastric acid secretion. Ranitidine is often referred to as Zantac, and is available in various forms, including tablet, injection, and effervescent tablet preparations.
The prevalence of GERD is thought to be 10-20% in western countries. Ranitidine has proven to be an effective treatment for relieving uncomfortable symptoms of gastric acid associated conditions and is therefore widely used in GERD and other gastric-acid related conditions.
This drug is used alone or with concomitant antacids for the following conditions: short-term treatment of active duodenal ulcer, treating gastric acid hypersecretion due to Zollinger-Ellison syndrome, systemic mastocytosis, and other conditions that may pathologically raise gastric acid levels. It also used in the short term treatment of active benign gastric ulcers and maintenance therapy of gastric ulcers at a reduced dose. In addition to the above, ranitidine can be used for the treatment of GERD symptoms, treatment of erosive esophagitis (endoscopically diagnosed) and the maintenance of gastric or duodenal ulcer healing.
Investigational Site Number 8400001, Houston, Texas, United States
Investigational Site Number 8400002, Atlanta, Georgia, United States
Investigational Site Number 2460001, Helsinki, Finland
George E Wahlen VA Medical Center, Salt Lake City, Utah, United States
Faculdade de Ciências Médicas da Santa Casa de São Paulo, Sao Paulo, Brazil
Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea, Republic of
Lucile Packard Children's Hospital Stanford, Palo Alto, California, United States
Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada
Investigational Site Number 392008, Kita-gun, Japan
Investigational Site Number 392001, Shinjuku-ku, Tokyo, Japan
Investigational Site Number 392004, Chuo-ku, Chiba, Japan
Investigational Site Number 056001, Brussels, Belgium
Investigational Site Number 528001, Breda, Netherlands
Investigational Site Number 528002, Rotterdam, Netherlands
Pamukkale Universty, Denizli, Turkey
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.